![\"Tandem](\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/08\/tandem-to-launch-tslim-x2-insulin-pump-with-dexcom-g5-mobile-cgm-integration-following-fda-approval-300x235.jpg\")
PLGS, or Predictive Low Glucose Suspend, Tandem\u2019s algorithm that will predict and prevent hypoglycemia events is coming next year. That\u2019s a fact. What I\u2019m curious to see is what\u2019s next. Operating in the world of upgradeable firmware (instead of just hardware) is a bit of a new journey for consumer health technology. While the FDA is working to speed up their approval process, there\u2019s certainly justification for adequate testing and validation of whatever new features that are being developed. That said, I\u2019m quite curious to see more about what Tandem has planned beyond PLGS<\/a>.<\/p>\n<\/p>\n
Bigfoot Biomedical<\/h2>\n
<\/p>\n <\/p>\n <\/p>\n Dexcom\u2019s API means your CGM data can show up in more places than just your receiver or phone. Dexcom and FitBit announced that early 2018 will bring the ability to see your CGM data on FitBit\u2019s Ionic Smartwatch<\/a>. What interests me is where else your data can show up as a result of Dexcom releasing their APIs to the world. I\u2019ll be keeping an eye on Dexcom\u2019s Developer Gallery<\/a> next year, and you should too.<\/p>\n <\/p>\n I haven\u2019t Looped. I don\u2019t run an OpenAPS rig. I have tremendous respect for the work being done at the tip of the spear of diabetes innovation within the open source community, but respectfully, it\u2019s not for me. That said, I look to this community for a glimpse at what may be possible \u201cout of the box\u201d for your typical person with diabetes who doesn\u2019t want to get in the weeds of Pull Requests and Edison Boards. Dana Lewis reports that she hasn\u2019t given herself a manual bolus in over 100 days<\/a>? If it\u2019s possible for the open source community, it should be possible for the device manufacturers with the resources to invest in developing a similar solution. I see the open source community as innovative fuel for diabetes solutions that I could never fathom on my own, and there\u2019s no telling what 2018 will bring.<\/p>\n <\/p>\n This one requires some disclosure. I\u2019m the Community Manager at Tidepool. We create free software that integrates diabetes data from a wide range of devices – pumps, CGMs, meters – into one place. Interoperability and open data protocols are at the heart of what we do. My hope is that 2018 ushers in a spirit of cooperation and collaboration that is desperately needed in healthcare. Diabetes is unique with the tools and technology that can be utilized to help manage this disease, but I don\u2019t want innovation if it comes with silos and closed development. The JDRF is in favor of open protocol automated insulin delivery systems<\/a>,<\/a> hopefully this enthusiasm carries on through 2018.<\/p>\n <\/p>\n My last note is a bit of a wildcard. Advocacy is going to play a crucial role in how a lot of all of these fantastic new options develop. If we can\u2019t afford insulin, then there\u2019s no way we can afford an automated insulin delivery system. I look to T1International<\/a> and the Diabetes Patient Advocacy Coalition (DPAC) to lead the way as we continue to fight for accessibility and affordability for our treatment and care. I can tie this in with my outlook on 2018 diabetes technology by reminding you all that DPAC has an app to help you stay up to date<\/a> on what concerns the diabetes community most. I don\u2019t blame anyone for wanting to run and hide from the political landscape in the United States, but if we won\u2019t fight for the change we need, who will?<\/p>\n What will you be keeping an eye on next year?<\/p>\n","protected":false},"excerpt":{"rendered":" …<\/p>\n","protected":false},"author":314,"featured_media":48103,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1437],"tags":[],"yoast_head":"\n![\"Bigfoot](\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/07\/bigfoot-biomedical-chooses-abbotts-libre-over-dexcoms-cgm-e1512659668157-296x300.jpg\")
\n All eyes are on the blue sasquatch as their pivotal clinical trial takes center stage in 2018<\/a>. After that it\u2019s on to the FDA for submission, review, and approval. They\u2019re anticipating a 2020 commercial release, but I just want to know: does it work? Ultimately, it will be exciting to have a new option for people with diabetes to consider as more and more technology moves in the direction of automation. And speaking of automation…<\/p>\n\u00a0<\/h2>\n
OmniPod Updates<\/h2>\n
![\"Insulet](\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/08\/OMNIPOD-LOGO-for-web-300x201.jpg\"){kind=logo}
Can you close a loop if you\u2019re wearing a tubeless pump? Insulet has a few updates coming, including the ability to control your pump with a phone through their Dash platform and Horizon, their automated insulin delivery system. Dash should be out in 2018, while pivotal trials for Horizon are expected to begin late next year. But the ones I\u2019m most excited for are their U200 and U500 systems, which will deliver more concentrated doses of insulin to people with diabetes who require more insulin.\u00a0<\/p>\nDexcom G6<\/h2>\n
![\"Diabetes](\"https:\/\/asweetlife.org\/wp-content\/uploads\/2017\/12\/diabetes-technology-in-2018-e1512657950279-300x194.png\")
The G6 should bring some much-needed quality of life improvements to Continuous Glucose Monitoring. No more fussing over acetaminophen and a longer (FDA approved) sensor life are great. But I\u2019m most excited by the potential of a no-calibration sensor. We can thank Abbott and their FreeStyle Libre for that one. Now that there\u2019s legitimate competition, the race to innovate should accelerate improvements for everyone. But Abbott won\u2019t be the only source of pressure for Dexcom in the coming years. With so many other systems relying on their data to automate insulin delivery: Tandem, Insulet, the Open Source community, they\u2019ve put themselves in quite a position to support the growing landscape of diabetes technology and innovation in the coming years.<\/p>\nDexcom Everywhere<\/h2>\n
Open Source Solutions<\/h2>\n
Interoperability<\/h2>\n
Advocacy<\/h2>\n